Inflammation critically contributes to cancer metastasis, in which myeloid-derived suppressor cells (MDSCs) are an important participant. Although MDSCs are known to suppress immune surveillance, their roles in directly stimulating cancer cell proliferation and metastasis currently remain unclear. Lysosomal acid lipase (LAL) deficiency causes systemic expansion and infiltration of MDSCs in multiple organs and subsequent inflammation. In the LAL-deficient (lal − / − ) mouse model, melanoma metastasized massively in allogeneic lal − / − mice, which was suppressed in allogeneic lal +/+ mice owing to immune rejection. Here we report for the first time that MDSCs from lal − / − mice directly stimulated B16 melanoma cell in vitro proliferation and in vivo growth and metastasis. Cytokines, that is, interleukin-1β and tumor necrosis factor-α from MDSCs are required for B16 melanoma cell proliferation in vitro. Myeloid-specific expression of human LAL (hLAL) in lal − / − mice rescues these malignant phenotypes in vitro and in vivo. The tumorpromoting function of lal − / − MDSCs is mediated, at least in part, through overactivation of the mammalian target of rapamycin (mTOR) pathway. Knockdown of mTOR, Raptor or Rictor in lal − / − MDSCs suppressed their stimulation on proliferation of cancer cells, including B16 melanoma, Lewis lung carcinoma and transgenic mouse prostate cancer-C2 cancer cells. Our results indicate that LAL has a critical role in regulating MDSCs' ability to directly stimulate cancer cell proliferation and overcome immune rejection of cancer metastasis in allogeneic mice through modulation of the mTOR pathway, which provides a mechanistic basis for targeting MDSCs to reduce the risk of cancer metastasis. Therefore MDSCs possess dual functions to facilitate cancer metastasis: suppress immune surveillance and stimulate cancer cell proliferation and growth.
INTRODUCTION
Inflammation has crucial roles at all stages of tumor development, from tumor initiation to metastatic progression. 1 Metastasis, the leading cause of cancer-associated mortality, requires close collaboration between cancer cells and inflammatory cells. 1 Lysosomal acid lipase (LAL) hydrolyzes cholesteryl esters and triglycerides in the lysosome of cells to generate free fatty acids and cholesterol. Genetic ablation of the lal gene in mice has resulted in a systemic increase of myeloid lineage cells, causing severe inflammation in multiple organs. 2, 3 We have previously reported spontaneous lung adenocarcinoma in transgenic mice with myeloid-specific overexpression of matrix metalloproteinase 12, 4 or apoptosis inhibitor 6 (Api6/AIM/Spα) 5 or dominantnegative peroxisome proliferators-activated receptor-γ, 6 all of which are downstream target or effector genes of LAL.
The neutral lipid metabolic pathway controlled by LAL has a critical role in the development and homeostasis of myeloidderived suppressor cells (MDSCs), and LAL deficiency led to the infiltration and accumulation of MDSCs in various organs of the mice.
2,3,7 LAL-deficient (lal − / − ) MDSCs arise from dysregulated production of progenitor cells in the bone marrow and have strong suppressive function on T cells. 2, 3, 7 MDSCs, characterized by the co-expression of myeloid-cell lineage differentiation antigen Gr-1 and CD11b in mice, are a heterogeneous population of immature myeloid cells at different stages of differentiation. 8 In lal − / − mice, almost all Gr-1 + cells are positive for CD11b. 5 Most lal −/− MDSCs stained double positive for Ly6G and Ly6C (collectively called Gr-1). 5 Numerous studies have shown that an immunosuppressive state of MDSCs favors primary tumor development, [9] [10] [11] [12] [13] [14] [15] but whether there is a direct stimulation of MDSCs on cancer cell proliferation and growth has not been confirmed. Therefore, the lal − / − animal model is a perfect system to address this issue. In humans, altered mononuclear phagocyte differentiation (increased CD14 + CD16
+ and CD14 + CD33 + cells, subsets of human MDSCs) has been reported with heterozygote carriers of LAL mutations. 16 Patient with mutations in the LAL gene has been reported to be associated with carcinogenesis. demonstrated that the mTOR pathway is overactivated in bone marrow-derived lal − / − MDSCs. 21 It is entirely unknown whether the activation of the mTOR pathway in lal − / − MDSCs has a role in tumor development and metastasis.
In the present study, we focused on the effects of lal − / − MDSCs on proliferation, growth and metastasis of cancer cells, especially B16 melanoma cells. Our study demonstrates for the first time that lal − / − MDSCs directly stimulate cancer cell proliferation, growth and metastasis by overactivation of the mTOR pathway in the allogeneic mouse model. These findings provide not only a mechanistic insight into the LAL deficiency in facilitating metastasis but also a potential target on MDSCs for antitumor therapy. , P o 0.0001) at 3 weeks posttumor cell injection (Figures 1a and b) . Next, B16 melanoma cells were injected into the tail veins of mice to detect metastatic potential. Two weeks after injection, more B16 melanoma colonies were observed in lal − / − mice at the distal lung and liver organs (Figure 1c ). Hematoxylin and eosin (H&E) staining revealed more neoplastic melanoma cells in the lungs of lal − / − mice than in those of lal +/+ mice ( Figure 1d ). Myeloid cell expansion is a major manifestation in lal − / − mice. 2, 3 To evaluate the effects of LAL in myeloid lineage cells on B16 melanoma cell metastasis, a doxycycline-inducible hLAL myeloid-specific expressing Tg/KO (transgenic/knockout) triple mouse model was used. 3, 7 Statistical analysis displayed that 2 weeks after intravenous injection of B16 melanoma cells, doxycycline-treated Tg/KO triple mice showed reduced number of melanoma colonies in the lungs compared with untreated mice (Figure 1e ), suggesting that hLAL expression in lal − / − myeloid cells partially restored immune rejection of B16 melanoma cells in the allogeneic mice model. In tumor growth assessment, B16 melanoma cells were subcutaneously injected into the flank region of Tg/KO triple mice. Figure 1f showed that the volume of tumors from doxycycline-treated Tg/KO triple mice was decreased by 50% compared with those developed in untreated mice at 2 weeks postinjection. Taken together, LAL in myeloid lineage cells has a critical role in rendering immune rejection of cancer cells in the allogeneic mouse model. (Figure 2b) . Therefore, lal − / − MDSCs possess a direct stimulatory activity on cancer cell proliferation.
RESULTS

LAL
LAL deficiency in
Activated MDSCs secrete cytokines that contribute to tumor cell invasion, proliferation and survival. 22 In lal − / − Ly6G + cells, mRNA levels of interleukin (IL)-1β and tumor necrosis factor (TNF)-α were upregulated by a real-time PCR analysis, while IL-6 showed no statistical difference (Figure 2c ). To examine whether these cytokines secreted by lal − / − Ly6G + cells facilitate melanoma cell proliferation, transwell study was performed with Ly6G + cells seeding in the upper chamber and melanoma cells in the lower chamber. After 72 h co-culture, the number of B16 melanoma cells that were co-cultured with lal − / − Ly6G + cells was significantly increased (Figure 2d ). When Ly6G + cells were treated with anti-IL-6, IL-1β or TNF-α antibodies to neutralize cytokines, the stimulatory effects on melanoma cell proliferation were significantly inhibited in the anti-TNF-α antibody-treated group. Although anti-IL-6 and anti-IL-1β antibodies showed no statistically significant effect, combination of all three cytokine antibodies further blocked the stimulatory effect of melanoma cell proliferation by lal − / − Ly6G + cells (Figure 2d ). Therefore, cytokines (especially TNF-α) secreted by lal − / − Ly6G + cells are, at least in part, responsible for mediating stimulatory effects on cancer cells.
LAL deficiency in Ly6G
+ cells facilitated B16 melanoma cell metastasis As lal − / − Ly6G + cells possess both immune suppressive function on T cells 3 and stimulatory function on cancer cells, it is intriguing to investigate whether lal − / − Ly6G + cells facilitate B16 melanoma cell metastasis. Two weeks after intravenous co-injection, melanoma metastasized more aggressively in allogeneic recipient lal mTOR inhibition impaired the ability of lal − / − Ly6G + cells to enhance B16 melanoma cell proliferation and growth We have recently reported that genes involved in the mTOR signaling pathway were altered in bone marrow-derived lal
Ly6G
+ cells by Affymetrix GeneChip microarray. 21 This was confirmed by western blotting assay, in which mTOR downstream effectors p70S6K and S6 were highly phosphorylated in lal 19 For in vitro co-culture study, Raptor and Rictor knockdown significantly reduced lal − / − Ly6G + cell stimulation of melanoma cell proliferation (Figure 6a) . Similarly, in the in vivo co-culture Matrigel assay, less neoplastic cells were detected in the plugs with Raptor and Rictor knockdown in lal − / − Ly6G + cells (Figure 6b ). For in vivo metastasis study, less melanoma metastatic lesions developed in the lungs of mice that were co-injected with B16 melanoma cells and Raptor or Rictor siRNA knockdown lal − / − Ly6G + cells, and H&E staining of lung sections showed significantly less neoplastic cells (Figure 6c ). Taken together, both mTORC1 and mTORC2 are involved in lal − / − Ly6G + cell stimulation on B16 melanoma cell proliferation, growth and metastasis.
LAL deficiency in Ly6G
+ cells stimulated Lewis lung carcinoma (LLC) and transgenic mouse prostate cancer (Tramp)-C2 proliferation and growth, which was reversed by mTOR inhibition To further confirm that lal − / − Ly6G + cells generally stimulate cancer cell proliferation and growth, the above experiments were repeated in two more cancer cell line models, LLC and Tramp-C2. In in vitro co-culture study, proliferation of LLC or Tramp-C2 was significantly increased after co-cultured with lal − / − Ly6G + cells (Figure 7a 
Ly6G
+ cells stimulate proliferation of multiple cancer cell models.
DISCUSSION
LAL is a key enzyme in the metabolic pathway of neutral lipids. Based on extensive characterization, LAL has a tight connection with inflammation, and its deficiency results in multiple pathogenic phenotypes. 2, 3, 7, 23, 24 Strikingly, this report discovered that LAL deficiency-induced inflammation alleviated the immune rejection by allowing melanoma growth (Figures 1a and b) and metastasis to multiple organs in the allogeneic lal − / − mouse model (Figure 1c) , suggesting that LAL is a critical lipid metabolic ) in 600 μl media were placed in the lower chamber. For the neutralization study, Ly6G + cells were treated with 10 μg/ml neutralizing antibody against IL-6, IL-1β, TNF-α individually or in combination or control immunoglobulin G. After 72 h, the number of B16 melanoma cells was counted. Data were expressed as mean ± s.d.; n = 4. ***P o0.001, **P o0.01, *Po 0.05. mTOR and MDSCs in cancer metastasis T Zhao et al enzyme in tumor immunology. Understanding the cellular and molecular mechanisms underlying this observation will help identify potential targets for antitumor therapies.
The occurrence of metastasis requires cancer cells to survive in the circulation, arrive at the target organs and show persistent proliferation and growth. 25 Such multi-step process is inefficient in the allogeneic mouse model due to immune rejection. However, metastasis can be facilitated by the inflammatory environment, especially by interacting with inflammatory cells. 1 As hLAL expression in lal − / − myeloid cells partially restored immune rejection of B16 melanoma cell in the allogeneic mouse model (Figures 1e and f) , the myeloid compartment must be crucial in controlling cancer cell growth and metastasis. One major manifestation during LAL deficiency is systemic MDSC expansion and dysfunction in multiple organs of the mice, 2,3,23,26,27 which arises from dysregulated production of myeloid progenitor cells in the bone marrow. 2 In lal − / − mice, most MDSCs are Ly6G and Ly6C double positive, which showed strong suppression on T-cell proliferation and function, 3 similar to those observed in tumorbearing mice. 14, 28, 29 As B16 melanoma cells metastasized massively in the allogeneic lal − / − mouse model, other unidentified functions of lal − / − MDSCs have been further explored in addition to their well-known immunosuppressive function.
Indeed, when bone marrow-derived lal − / − MDSCs were cocultured with B16 melanoma cells in vitro, a direct stimulatory effect of lal − / − MDSCs on cancer cell proliferation was observed (Figure 2a ). This process was partially mediated by several inflammatory cytokines secreted by lal − / − MDSCs (Figures 2c  and d) . This was further supported by in vivo Matrigel assay when lal − / − MDSCs and B16 melanoma cells were co-injected into allogeneic recipient lal +/+ mice, which showed more robust cancer cell growth in vivo (Figure 2b ). To our knowledge, this is the first study demonstrating that MDSCs are able to directly stimulate cancer cell proliferation both in vitro and in vivo. Importantly, proliferation of other cancer cell lines (LLC and Tramp-C2) was also directly stimulated by lal − / − MDSCs in vitro and in vivo (Figures 7a-c) . Therefore, MDSCs not only possess immunosuppressive function to clear a way for cancer growth and progression but also stimulate cancer cell proliferation directly. In these processes, LAL in myeloid cells is critically involved in controlling the immunosuppressive function and cancer cell proliferationstimulating function, because MDSCs isolated from hLAL myeloid specifically expressed lal − / − mice showed reduced ability to suppress T-cell proliferation and function 3 and impaired stimulation on cancer cell proliferation (Figures 2a and b) Given the importance of lal − / − MDSCs in cancer cell metastasis, it is important to identify the molecular mechanisms that mediate lal − / − MDSCs malfunction, especially their stimulation on cancer cell proliferation. Identification of such mechanisms and pathways will help find pharmacological intervention in immune therapy for cancer treatment. To achieve this goal, the intrinsic molecular defects in lal − / − MDSCs were identified by Affymetrix GeneChip microarray analysis. Ingenuity Pathway Analysis of gene transcripts revealed upregulation of multiple genes in the mTOR signaling pathway in lal − / − MDSCs. The mTOR-associated cellular defects, including increased reactive oxygen species production, elevated ATP synthesis and reduced membrane potential, have been observed in lal − / − MDSCs as we reported previously. 21 So far, no study has been carried out to evaluate whether and how the mTOR pathway in MDSCs influences cancer immunology. In the present study, we confirmed that LAL deficiency induced overactivation of the mTOR pathway in MDSCs by activating the mTOR downstream genes (Figure 4a) . Inhibition of mTOR in lal
MDSCs by siRNA transfection not only impaired their stimulatory effects on cancer cell proliferation in in vitro co-culturing assay (Figures 4b and 7d ) and in vivo Matrigel assay (Figures 4c and d) but also significantly retarded their ability on B16 melanoma cell metastasis ( Figure 5 ). Tumor-associated F4/80 + macrophages, CD3 + T cells and CD31 + endothelial cells in the B16 melanoma cell-injected Matrigel plugs were also reduced after inhibition of mTOR in lal − / − MDSCs by siRNA transfection (Figure 4d ), suggesting that overactivation of the mTOR pathway in lal
MDSCs is a major molecular mechanism underlying their stimulatory effects on cancer cell proliferation and metastasis. Furthermore, both mTORC1 and mTORC2 were involved in the lal − / − MDSCs' stimulatory activity on B16 melanoma cell proliferation, growth and metastasis ( Figure 6 ). In addition to lal − / − MDSCs, inhibition of mTOR, Raptor and Rictor also showed effects in lal +/+ MDSCs (Figures 2, 6 and 7) . The mTOR signaling pathway is involved in regulating cell growth, proliferation, MDSCs development from lineage-negative progenitor cells; and (4) reversed the immune suppression on T-cell proliferation and function that are associated with decreased reactive oxygen species production and recovery from impairment of mitochondrial membrane potential. 19 These results indicate a critical role of LAL-regulated mTOR signaling in the production and function of lal − / − MDSCs.
In conclusion, neutral lipid metabolism controlled by LAL critically regulates MDSCs' ability to directly stimulate cancer cell proliferation, metastasis and immune suppression through modulation of the mTOR pathway. The mTOR pathway may be served as a novel target to modulate the emergence of MDSCs to reduce the risk of cancer metastasis. is a previously generated triple transgenic mouse model with myeloidspecific doxycycline-inducible expression of wild-type human LAL (hLAL) in lal − / − mice under the control of the c-fms promoter. 3, 7 All scientific protocols involving the use of animals have been approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine and followed guidelines established by the Panel on Euthanasia of the American Veterinary Medical Association. Animals were housed under Institutional Animal Care and Use Committee-approved conditions in a secured animal facility at the Indiana University School of Medicine.
MATERIALS AND METHODS
Animals and cell lines
The murine B16 melanoma cell line, LLC cell line and transgenic mouse prostate cancer (Tramp-C2) cell line (purchased from ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA).
Isolation of bone marrow-derived MDSCs
MDSCs were isolated as we previously described. 6, 21 Briefly, bone marrow cells were isolated from the femurs and tibias of mice. Cells were first incubated with biotin-conjugated anti-Ly6G antibody at 4°C for 15 min. After washing with phosphate-buffered saline (PBS), cells were then incubated with anti-biotin microbeads at 4°C for another 15 min. Subsequently, cells were subjected to magnetic bead sorting according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA, USA).
In vitro co-culture of MDSCs and B16 melanoma cells A pilot study has been performed to determine the best ratio between MDSCs and B16 melanoma cells. B16 melanoma cells were harvested, resuspended and adjusted to density at 5 × 10 4 cells/ml. Isolated MDSCs were used immediately, and the cell density was adjusted to 5 × 10 6 cells/ ml. One hundred microliter of MDSCs and 100 μl of B16 melanoma cells were mixed and seeded into a well of 96-well plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Seventy-two hours later, unattached MDSCs were removed by washing with PBS, and the number of attached B16 melanoma cells was counted. Morphologically, MDSCs are much smaller than B16 melanoma cells for exclusion.
In vivo Matrigel plug assay with MDSCs and B16 melanoma cells
This assay was performed according to an established method with minor modifications. 30 MDSCs and B16 melanoma cells were collected separately. + cells were transfected with mTOR siRNA or control (C) siRNA for 24 h, followed by co-culture with cancer cells in vitro. The numbers of LLC or Tramp-C2 cells were counted after 72 h. Data were expressed as mean ± s.d.; n = 4. *P o0.05, **P o0.01. mTOR and MDSCs in cancer metastasis T Zhao et al
